|
Collaboration Arrangements - Additional Information (Detail) (USD $)
In Millions, unless otherwise specified |
3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 14 Months Ended | 9 Months Ended | ||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2013
|
Sep. 30, 2012
|
Sep. 30, 2013
|
Sep. 30, 2012
|
Mar. 31, 2013
Merck KGaA [Member]
|
Sep. 30, 2013
Merck KGaA [Member]
|
Mar. 31, 2013
Merck KGaA [Member]
|
Sep. 30, 2013
Merck KGaA [Member]
Regulatory and development milestones [Member]
|
Sep. 30, 2013
Merck KGaA [Member]
Regulatory and development milestones [Member]
2013 Potential Milestone payments [Member]
|
Sep. 30, 2013
Merck KGaA [Member]
Commercialization milestones [Member]
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||||||
| Upfront payment received | $ 25 | |||||||||
| Milestone payments received to date | 42.5 | 72.5 | ||||||||
| Potential future milestones | 112.5 | 12.5 | 340.0 | |||||||
| Merck's percentage share of worldwide development expenses | 70.00% | |||||||||
| Portion of profits that Company is eligible to participate in United States, depending upon total sales | 50.00% | |||||||||
| Revenue recognized by the Company | 3.2 | 1.8 | 9.3 | 3.8 | ||||||
| Collaboration payments achieved and received | 30.0 | 97.5 | ||||||||
| Company earned a reimbursement for eligible worldwide development expenses | $ 5.5 | $ 5.0 | $ 11.6 | $ 10.0 | ||||||